MedTrace Logo

N- Homocysteinylated Huntingtin in Huntington's Disease

NCT05225051 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2022-03-09

No results posted yet for this study

Summary

Descriptive analysis of N- homocysteinylated Huntingtin in 3 groups of human fibroblasts:

1. presymptomatic HD individuals with UHDRS motor ≤ 5 (Mutated Huntingtin),
2. symptomatic HD individuals with motor UHDRS \> 5 (Mutated Huntingtin)
3. human control cell lines, unmutated Huntingtin

Conditions

  • Huntington Disease

Interventions

OTHER

skin biopsy

skin biopsy

Sponsors & Collaborators

  • Central Hospital, Nancy, France

    lead OTHER

Principal Investigators

  • Mathilde Renaud · CHRU Nancy

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2023-05-01
Completion
2023-05-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05225051 on ClinicalTrials.gov